6066 RESULTS
Sort By:
While the FDA weighs aducanumab’s marketing license application, Alzheimer’s researchers agree that the agency’s own statistician correctly assessed the data as weak. Most prefer that one more trial be done.
Discoverer of ApoE4 risk allele died of a heart attack.
For the first time, NIA-AA proposal bases diagnosis in living people solely on biomarkers for plaques and tangles.
Desikan pioneered advances in neuroimaging and neurogenetics, and was known for his passion and collaborative spirit.
The Phase 2 trial provides the strongest evidence yet that removing most amyloid from the brain bolsters cognition, although the benefit is small.
Bapineuzumab prevents accumulation of Aβ in the brain and lowers phospho-tau (p-tau) in cerebrospinal fluid (CSF), according to analysis...
It is with deep sadness that we inform the Alzheimer research community of the passing of Anne Cataldo...
Friends and colleagues grapple with the loss of this young investigator.
In efforts to interfere with Aβ peptide production, most of the attention has been lavished on the β- and γ-secretase enzymes...
Researchers consider the data encouraging, though questions linger about the cognition results. Did regulators mess up the randomization of this trial?
Vascular troubles preceded amyloid deposition and other disease markers in a new Alzheimer’s progression model based on ADNI data.
The Phase 3 APECS trial of Merck’s flagship BACE inhibitor ends prematurely following an interim safety analysis.
Network analysis of human PET brain imaging data suggests amyloid plaques set the stage for microglial activation that, in turn, drives tangle spread through the brain.
People with subjective or mild cognitive impairment are less likely to get dementia if their CSF Aβ38 levels are high. Should γ-secretase modulators be revived?
Fungal cells cropped up in multiple brain regions of all AD brains examined, but how they got there and what they are doing remains mysterious.
No filters selected
